Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective

• Published in: European journal of cancer (1990) 1998-11, Vol.34 (12), p.1894-1901
• Main Authors: Berger, K., Fischer, T., Szucs, T.D.
• Format: Article
• Language: English
• Subjects: Adult; advanced ovarian cancer; Aged; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - economics; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Chemotherapy; cisplatin; Cisplatin - administration & dosage; Cisplatin - economics; Cost-Benefit Analysis; cost-effectiveness analysis; cyclophosphamide; Cyclophosphamide - administration & dosage; Cyclophosphamide - economics; Europe; European perspective; Female; Health Care Costs; Humans; Medical sciences; Middle Aged; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - economics; paclitaxel; Paclitaxel - administration & dosage; Paclitaxel - economics; Pharmacology. Drug treatments; Retrospective Studies; Sensitivity and Specificity
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/S0959-8049(98)00260-3

Paclitaxel is a new cytotoxic agent that has demonstrated significant activity in advanced ovarian cancer. The aim of this study was to determine the cost structure of advanced ovarian cancer and the cost-effectiveness of paclitaxel–cisplatin (PC) combination therapy compared with a standard cyclophosphamide–cisplatin (CC) regimen as first-line therapy. The analysis was performed separately for six European countries: Germany, Spain, France, Italy, The Netherlands and the U.K. The study was conducted from the national health service payer’s perspective. The total cost of treatment per patient (six cycles of chemotherapy) in the six European countries varied between a minimum of US$4,926 in the U.K. and US$12 578 in Germany for the CC regimen and between US$13 038 and US$24 487 for the PC regimen (April 1996). Since the new regimen improved life expectancy by 1.283 years compared with CC, the incremental cost-effectiveness of PC was calculated to be between US$6,403 per 5-year saved in the U.K. and US$11 420 per life-year saved in Italy. Overall, the cost-effectiveness of PC compares favourably with other oncological interventions. The findings of this study suggest that healthcare decision makers should consider paclitaxel, in combination with cisplatin, as a cost-effective first-line therapy for patients with advanced ovarian cancer.